Company Profile

SomaLogic, Inc. is a commercial-stage proteomics company. The Company has built an integrated proteomics platform, which offers throughput proteomics analysis with broad proteome coverage. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. It offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaScan Certified Sites, SomaSignal Tests and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. Its SOMAmer reagents are proprietary modified aptamers, which are short, synthetic single-stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.

Employees

451

Sector

Biotechnology & Medical Research

More about the company

25-06-23	Illumina, Inc. entered into an agreement to acquire SomaLogic, Inc. from Standard BioTools Inc. for approximately $430 million.	CI
24-01-10	Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P Global BMI Index	CI
24-01-10	Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P TMI Index	CI
24-01-08	Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023	CI
24-01-05	Declaration of Voting Results by SomaLogic Inc	CI
24-01-05	Declaration of Voting Results by SomaLogic Inc	CI
24-01-05	Declaration of Voting Results by SomaLogic Inc	CI
24-01-05	Declaration of Voting Results by SomaLogic Inc	CI
24-01-05	Declaration of Voting Results by SomaLogic Inc	CI
24-01-05	Standard BioTools Says Merger With SomaLogic Completed	MT
24-01-05	SomaLogic, Standard BioTools Receive Shareholder Approvals for Pending Merger	MT
24-01-05	SomaLogic, Inc.(NasdaqGM:SLGC) dropped from NASDAQ Composite Index	CI
24-01-04	Madryn Asset Addresses SomaLogic?s Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools	CI

23-10-05	Jefferies Downgrades SomaLogic to Hold From Buy, Adjusts Price Target to $2.30 From $3.50	MT
23-09-25	Canaccord Genuity Downgrades SomaLogic to Hold From Buy, Cuts Price Target to $2.50 From $5	MT
23-03-29	Canaccord Genuity Adjusts Price Target on SomaLogic to $5 From $6, Maintains Buy Rating	MT
22-08-16	Stifel Nicolaus Adjusts SomaLogic Price Target to $8 From $12, Maintains Buy Rating	MT
22-08-16	Cowen Adjusts SomaLogic's Price Target to $9 From $11, Keeps Outperform Rating	MT

24-01-04	Standard BioTools Stockholders Approve Merger with SomaLogic	AQ
24-01-04	SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting	PR
24-01-04	Madryn Asset Management Demands SomaLogic’s Board Address Repeated, Unprecedented Adjournments of Tainted Special Meeting	BU
24-01-04	Madryn Asset Management Addresses SomaLogic’s Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools	BU
24-01-03	Proxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools	BU

Director	Title	Age	Since
Jeffrey Black BRD	Director/Board Member	57	2024-01-04
Hanjoon Kim BRD	Director/Board Member	55	2024-01-04

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/5/24	Ruben Gutierrez	Issuer sale	General Counsel	720,114	0.3817%
1/5/24	Thomas Carey	Issuer sale	Director	185,400	0.0983%
1/5/24	Casdin Capital LLC	Issuer sale	Company	12,604,275	6.6803%

Standard BioTools Inc. Stock

Stocks

SLGC

US83444K1051

Biotechnology & Medical Research

Latest news : Standard BioTools Inc.

Analysts' recommendations : Standard BioTools Inc.

Press Releases : Standard BioTools Inc.

Quotes and Performance

Managers and Directors : Standard BioTools Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STANDARD BIOTOOLS INC.	-4.55%	-17.00%	-	-	396M
LONZA GROUP AG	-0.71%	-6.35%	-2.99%	+9.37%	45.48B
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+337.74%	+520.30%	43.68B
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+39.82%	+20.85%	43.09B
BEONE MEDICINES AG	+1.38%	-3.28%	+6.84%	+73.19%	39.4B
CELLTRION, INC.	-1.44%	-5.26%	+8.97%	+39.76%	31.91B
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	17.31B
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+19.75%	+108.58%	16.4B
EUROFINS SCIENTIFIC SE	-0.31%	-2.78%	+10.78%	+30.20%	14.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+82.00%	+36.66%	13.28B
Average	-0.01%	-3.20%	+62.86%	+104.87%	29.42B
Weighted average by Cap.	+0.40%	-3.50%	+74.57%	+124.86%